Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.17 -2.7%	$1.88	$1.41 ▼ $2.79	$98.56M	1.47	79,831 shs	64,352 shs
ERAS Erasca	$1.46 +2.1%	$1.35	$1.01 ▼ $3.45	$413.57M	1.14	1.87 million shs	739,620 shs
PRTC PureTech Health	$17.26 -1.4%	$17.42	$13.30 ▼ $32.98	$414.57M	1.12	4,675 shs	1,114 shs
SANA Sana Biotechnology	$1.90 +11.1%	$2.04	$1.26 ▼ $10.50	$385.57M	1.78	3.31 million shs	2.87 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	-2.19%	+13.78%	+27.43%	-6.30%	+10.95%
ERAS Erasca	+2.14%	+3.62%	-5.92%	-22.28%	-29.90%
PRTC PureTech Health	+2.21%	+0.66%	-9.51%	-7.27%	-38.60%
SANA Sana Biotechnology	-2.84%	-1.16%	0.00%	-47.38%	-81.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTX Entera Bio	2.159 of 5 stars	3.5	4.0	2.2	0.8	0.0
ERAS Erasca	3.1273 of 5 stars	3.5	2.0	2.8	3.3	1.3
PRTC PureTech Health	2.3346 of 5 stars	3.8	3.0	2.7	0.0	0.6
SANA Sana Biotechnology	1.9082 of 5 stars	3.4	0.0	1.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	3.00	Buy	$10.00	360.83% Upside
ERAS Erasca	3.00	Buy	$4.83	231.05% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	160.72% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	468.42% Upside

Current Analyst Ratings Breakdown

Latest ENTX, PRTC, ERAS, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/26/2025	ERAS Erasca	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/21/2025	ERAS Erasca	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/21/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/18/2025	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/18/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/18/2025	SANA Sana Biotechnology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00
3/14/2025	SANA Sana Biotechnology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
3/7/2025	ERAS Erasca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$4.00 ➝ $4.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$181K	544.55	N/A	N/A	$0.36 per share	6.03
ERAS Erasca	N/A	N/A	N/A	N/A	$2.10 per share	N/A
PRTC PureTech Health	$3.33M	124.49	N/A	N/A	$16.94 per share	1.02
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$8.89M	-$0.25	N/A	N/A	N/A	N/A	-107.24%	-92.29%	5/9/2025 (Estimated)
ERAS Erasca	-$125.04M	-$0.74	N/A	N/A	N/A	N/A	-42.26%	-34.97%	5/14/2025 (Estimated)
PRTC PureTech Health	-$65.70M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	4/30/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$1.16	N/A	N/A	N/A	N/A	-84.22%	-44.97%	5/6/2025 (Estimated)

Latest ENTX, PRTC, ERAS, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ERAS Erasca	-$0.12	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	N/A	N/A	N/A	N/A	N/A
5/9/2025	Q1 2025	ENTX Entera Bio	-$0.07	N/A	N/A	N/A	N/A	N/A
3/28/2025	Q4 2024	ENTX Entera Bio	-$0.08	-$0.06	+$0.02	-$0.06	$0.04 million	$0.04 million
3/20/2025	Q4 2024	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	6.61	6.61
ERAS Erasca	N/A	11.00	11.00
PRTC PureTech Health	N/A	3.68	N/A
SANA Sana Biotechnology	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
ERAS Erasca	67.78%
PRTC PureTech Health	0.04%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.90%
ERAS Erasca	21.50%
PRTC PureTech Health	5.30%
SANA Sana Biotechnology	31.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	20	45.42 million	31.88 million	Optionable
ERAS Erasca	120	283.27 million	221.94 million	Optionable
PRTC PureTech Health	100	24.02 million	22.67 million	Not Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable

ENTX, PRTC, ERAS, and SANA Headlines

Recent News About These Companies

Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA

April 30 at 9:10 PM | accessnewswire.com

Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA

April 30 at 7:30 PM | accessnewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA

April 30 at 7:00 PM | accessnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

April 30 at 5:45 PM | accessnewswire.com

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA

April 30 at 4:18 PM | globenewswire.com

Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

April 30 at 10:15 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

April 30 at 9:40 AM | accessnewswire.com

Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

April 30 at 7:25 AM | accessnewswire.com

SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 30 at 7:00 AM | accessnewswire.com

SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 29 at 10:00 PM | accessnewswire.com

Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky About Pending Class Action - SANA

April 29 at 4:30 PM | accessnewswire.com

Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline

April 29 at 1:10 PM | globenewswire.com

SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 29 at 9:45 AM | accessnewswire.com

SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 29 at 9:30 AM | prnewswire.com

Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

April 29 at 8:15 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA

April 29 at 8:00 AM | globenewswire.com

Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

April 29 at 7:30 AM | accessnewswire.com

SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 29 at 7:00 AM | accessnewswire.com

Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

April 29 at 5:45 AM | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

April 28 at 8:30 PM | accessnewswire.com

XTX Topco Ltd Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA)

April 27 at 4:03 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, PRTC, ERAS, and SANA Company Descriptions

Entera Bio NASDAQ:ENTX

$2.17 -0.06 (-2.69%)

As of 04:00 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Erasca NASDAQ:ERAS

$1.46 +0.03 (+2.10%)

As of 04:00 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

PureTech Health NASDAQ:PRTC

$17.26 -0.24 (-1.37%)

As of 03:48 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$1.90 +0.19 (+11.11%)

As of 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time